Genmab A/S
A Denmark-based biopharmaceutical company focused on developing antibody therapeutics.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Genmab's stock with a target price of $39.2, indicating strong growth potential.
Financial Health
Genmab is achieving strong sales and profits, with significant cash generation and high profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GMAB
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory decisions can be major value drivers, though trial outcomes are uncertain and timelines can shift.
Partner-led Revenue
Collaborations with large pharmaceutical firms provide milestone and royalty income, offering diversification but depending on partner execution.
Proprietary Platforms
Genmab’s antibody technologies can speed discovery and create long-term opportunity, while commercial success still depends on competition and execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
